Breast Cancer Clinical Trial
Official title:
Randomized, Controlled Trial of an Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients
| Verified date | June 2024 |
| Source | Kettering Health Network |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
To test the effect of an individualized exercise oncology program on healthcare utilization, 30-day hospital readmission, pain, and cancer treatment tolerance.
| Status | Completed |
| Enrollment | 251 |
| Est. completion date | October 28, 2021 |
| Est. primary completion date | October 28, 2021 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 30 Years to 80 Years |
| Eligibility | Inclusion Criteria: - Female; determined from electronic medical record - Initial stage 0, 1 or 2 breast cancer diagnosis within the past 12 weeks determined from electronic medical record - Age 30-80; determined from electronic medical record - Physician clearance to participate in exercise Exclusion Criteria: - Participation in supervised physical exercise within 6 months prior to study enrollment - Currently pregnant or planning to become pregnant - Non-English speaking - Unable to make own medical decisions and/or to follow verbal instructions |
| Country | Name | City | State |
|---|---|---|---|
| United States | Maple Tree Cancer Alliance | Dayton | Ohio |
| Lead Sponsor | Collaborator |
|---|---|
| Karen Wonders |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Missed Fractions | Total number of missed fractions, determined by electronic medical record | 12 weeks | |
| Primary | Numbers of Breaks in Cancer Treatment | Defined as missing 3 or more fractions due to patient condition, determined by electronic medical record | 12 weeks | |
| Primary | Cost of Emergency Room Visits | Medical expenditure and utilization, for each time a patient utilized an emergency room visit for the purpose of managing health problems in addition to the planned cancer care, determined by electronic medical record. | 12 weeks | |
| Primary | Encounters | Number of inpatient and outpatient hospital encounters, determined by electronic medical record | 12 weeks | |
| Primary | Cost of Total Unplanned Expenditures | Number of hospital readmissions for the same presenting issue, determined by electronic medical record | 12 weeks | |
| Primary | Cost of Hospital Inpatient Care | Hospital length of stay, in days, if applicable. Determined by electronic medical record. | 12 weeks | |
| Primary | Cancer Treatment Adherence | Percentage of patient adherence to their cancer treatment, determined by electronic medical record | 12 weeks | |
| Primary | Cancer Treatment Symptom Management Medications | Number of the different types of medications taken by patients for symptom management during their cancer treatment. Determined by electronic medical record. | 12 weeks | |
| Primary | Cancer Treatment Related Side Effects | Total number of cancer treatment related side effects | 12 weeks | |
| Primary | Patient Rated Pain Score | The Short Form-36 survey was used to measure pain. A high score defines a more favorable health state. Each item is scored on a 0 to 100 range, with the lowest and highest possible scores being 0 and 100, respectively. | 12 weeks, measured at the start of their exercise program during their initial assessment and at the 12-week follow-up re-assessment. | |
| Primary | Cancer TreatmentTtolerance | Measured by the Eastern Cooperative Oncology Group (ECOG) performance status score. Scale is from 0 to 5, with 0 being high functioning and no restriction and 5 being dead. | 12 weeks - ECOG performance status measurements were recorded at baseline and at the 12-week follow up appointment. | |
| Primary | Quality of Life Measure: Utilizing McGill Quality of Life Survey and FACT-B Questionnaire | McGill Quality of Life Survey:
Physical Wellbeing (questions 1-4) - minimum score is 0, maximum score is 40. A higher score would be good and lower score would be bad. Social Wellbeing (questions 12, 14-16) - minimum score is 0, maximum score is 40. A higher score would be good and lower score would be bad. Emotional Wellbeing(questions 5-7, 13) - minimum score is 0 and maximum score is 40. A higher score would be bad and a lower score would be good Functional wellbeing (questions 8-11) - minimum score is 0, maximum score is 40. A higher score would be good and lower score would be bad. FACT-BREAST Survey: Minimum score is 0 and maximum is 148; 0 is not at all and 4 is very much, "good" or "bad" varies depending on the question; overall a higher score is good and a lower score is bad |
Baseline was at the time of enrollment and follow up was after 12-weeks. | |
| Secondary | Adherence Rate | Exercise session adherence rate among the Exercise Group, collected from the Maple Tree Cancer Alliance participant records. Exercise session adherence rate was measured by dividing the total number of sessions scheduled by the total number of exercise sessions actually attended by the exercise group. | 12 weeks | |
| Secondary | Percentage of Participants Who Completed the Study (Attrition Rate) | Exercise program attrition rate among the Exercise Group, collected from the Maple Tree Cancer Alliance participant records. Attrition was determined by calculating the percent of participants who completed the study by the total number of participants who started the study. | 12 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |